These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6974957)

  • 1. Polymorphic acetylator phenotype and systemic lupus erythematosus.
    Johansson E; Mustakallio KK; Mattila MJ
    Acta Med Scand; 1981; 210(3):193-6. PubMed ID: 6974957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylator phenotype in systemic lupus erythematosus.
    Foad B; Litwin A; Zimmer H; Hess EV
    Arthritis Rheum; 1977 Apr; 20(3):815-8. PubMed ID: 301027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug acetylation and expression of lupus erythematosus.
    Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S
    Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No demonstrable relationship between IgM and IgG antinuclear antibody levels and acetylator phenotype in patients with systemic lupus erythematosus.
    Portanova JP; Small CJ; Kohler PF
    Arthritis Rheum; 1985 Sep; 28(9):995-8. PubMed ID: 3899125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus.
    Morris RJ; Freed CR; Kohler PF
    Arthritis Rheum; 1979 Jul; 22(7):777-80. PubMed ID: 454504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.
    Lawson DH; Henry DA; Lowe J; Reavey P; Rennie JA; Solomon A
    Ann Rheum Dis; 1979 Apr; 38(2):171-3. PubMed ID: 443884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
    Horai Y; Ishizaki T; Sasaki T; Koya G; Matsuyama K; Iguchi S
    Br J Clin Pharmacol; 1982 Mar; 13(3):361-74. PubMed ID: 7059436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous systemic lupus erythematosus and acelylator phenotype.
    Larsson R; Karlsson E; Molin L
    Acta Med Scand; 1977; 201(3):223-6. PubMed ID: 848361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of the human acetylator polymorphism in spontaneous disorders.
    Evans DA
    J Med Genet; 1984 Aug; 21(4):243-53. PubMed ID: 6387123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotype in idiopathic systemic lupus erythematosus.
    Reidenberg MM; Levy M; Drayer DE; Zylber-Katz E; Robbins WC
    Arthritis Rheum; 1980 May; 23(5):569-73. PubMed ID: 7378086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus.
    Ishizaki T; Horai Y; Koya G; Matsuyama K; Iguchi S
    Arthritis Rheum; 1981 Oct; 24(10):1245-54. PubMed ID: 7306226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal distribution of acetylation phenotypes in systemic lupus erythematosus.
    Vansant J; Woosley RL; John JT; Sergent JS
    Arthritis Rheum; 1978 Mar; 21(2):192-5. PubMed ID: 637885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antinuclear antibodies related to acetylator phenotype in mice.
    Tannen RH; Weber WW
    J Pharmacol Exp Ther; 1980 Jun; 213(3):485-90. PubMed ID: 6970809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus.
    Baer AN; Woosley RL; Pincus T
    Arthritis Rheum; 1986 Apr; 29(4):508-14. PubMed ID: 3707628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype.
    Russell GI; Bing RF; Jones JA; Thurston H; Swales JD
    Q J Med; 1987 Oct; 65(246):845-52. PubMed ID: 3329739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function.
    Hall S
    Acta Med Scand; 1981; 209(6):505-7. PubMed ID: 7257867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.